# 1 Cell-density independent increased lymphocyte production and loss rates post-autologous

# 2 hematopoietic stem cell transplantation

- 3 Mariona Baliu-Piqué<sup>1\*</sup>, Vera van Hoeven<sup>2\*</sup>, Julia Drylewicz<sup>1\*</sup>, Lotte E. van der Wagen<sup>3</sup>, Anke Janssen<sup>1</sup>,
- 4 Sigrid A. Otto<sup>1</sup>, Menno C. van Zelm<sup>4</sup>, Rob J. de Boer<sup>5</sup>, Jürgen Kuball<sup>1,3</sup>, José A.M. Borghans<sup>1\*</sup> and Kiki
- 5 Tesselaar<sup>1\*</sup>
- 6 <sup>1</sup>Center for Translational Immunology, University Medical Center Utrecht, The Netherlands;
- 7 <sup>2</sup>Department of Experimental Immunology, Amsterdam UMC, University of Amsterdam, The Netherlands;
- 8 <sup>3</sup>Department of Hematology, University Medical Center Utrecht, The Netherlands;
- <sup>4</sup>Department of Immunology and Pathology, Monash University and Alfred Hospital, Melbourne;
- 10 <sup>5</sup>Theoretical Biology, Utrecht University, Utrecht, The Netherlands
- 11 \*These authors contributed equally to this work

# 12 Corresponding author:

- 13 Kiki Tesselaar, PhD
- 14 Center for Translational Immunology
- 15 University Medical Center Utrecht (UMCU)
- 16 P.O. Box 85090, 3508 AB Utrecht, The Netherlands
- 17 T: +31 (0)88755394; E-mail: K.Tesselaar@umcutrecht.nl

# 18 Abstract

19 Lymphocyte numbers need to be quite tightly regulated. It is generally assumed that 20 lymphocyte production and survival rates increase homeostatically when lymphocyte numbers 21 decrease. This widely-accepted concept is largely based on experiments in mice. In humans, 22 lymphocyte reconstitution usually occurs very slowly, which challenges the idea that density 23 dependent homeostasis aids recovery from lymphopenia. Using in vivo deuterium labelling, we 24 quantified lymphocyte production and survival rates in patients who underwent an autologous 25 hematopoietic stem cell transplantation (autoHSCT). We indeed found that the production rates of 26 most T-cell and B-cell subsets in autoHSCT-patients were 2 to 8-times higher than in healthy controls. 27 These increased lymphocyte production rates went hand in hand with a 3 to 9-fold increase in cell loss 28 rates, and both rates did not normalize when cell numbers did. This challenges the concept of 29 homeostatic regulation of lymphocyte production and survival rates in humans.

30

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# 31 Introduction

Under healthy conditions, the peripheral T- and B-cell populations are maintained at relatively 32 stable numbers throughout life <sup>1,2</sup>. Homeostatic mechanisms are thought to regulate lymphocyte 33 34 production and survival rates in a density-dependent manner. Indeed, studies in rodents have shown 35 that lymphocyte division and survival rates increase in response to severe lymphopenic conditions <sup>3</sup>. Robust peripheral proliferation of T-cells occurs both upon adoptive cell transfer into severely 36 37 lymphocyte-depleted mice, and in partially immune-depleted hosts in the absence of adoptive cell transfer, a phenomenon termed lymphopenia-induced proliferation (LIP) <sup>3–6</sup>. Similarly, rapid 38 39 proliferation and extended survival of B-cells occur after adoptive cell transfer into B-cell deficient hosts and correlate with peripheral B-cell numbers <sup>7</sup>. 40

41 In analogy, it is generally assumed that lymphopenic conditions induce alterations in lymphocyte 42 dynamics in humans. However, in humans full recovery of the T-cell compartment following an autologous hematopoietic stem cell (autoHSCT) is notoriously slow, often taking several years <sup>8–11</sup>. 43 On the basis of elevated frequencies of Ki-67<sup>+</sup> cells, severe lymphopenia arising after HSCT and 44 lymphocyte-depleting treatments has been associated with increased proliferation of naive and 45 memory T-cells <sup>12–15</sup>. However, elevated frequencies of Ki-67<sup>+</sup> cells were shown to decline within 3 to 46 47 6 months after cell depletion, despite the fact that patients were still deeply lymphopenic <sup>13–15</sup>. Furthermore, increased T-cell proliferation rates after allogeneic HSCT have been shown to correlate 48 with the occurrence of graft-versus-host disease (GVHD) and infectious-disease-related 49 50 complications <sup>14</sup>. Together, these observations question whether homeostatic mechanisms are 51 induced to compensate for low lymphocyte numbers in humans undergoing HSCT. It remains unclear to what extent increased T-cell proliferation post-HSCT reflects a T-cell density-dependent response to 52 lymphopenia, or an immune response triggered by therapy-related tissue damage, infectious 53 54 complications, or immune activation.

55 To elucidate whether lymphocyte production and death rates in humans are regulated in a 56 density-dependent manner, we used in vivo deuterium labelling to quantify the production and loss rates of different T- and B-cell subsets in patients who received an autologous HSCT (autoHSCT), and 57 58 had no signs of clinically manifested infections or GVHD. Twelve months after autoHSCT, absolute numbers of CD4<sup>+</sup>T-cells and memory and natural effector B-cells in these patients were still lower than 59 in healthy individuals, while CD8<sup>+</sup> T-cell and naive B-cell numbers had already recovered to healthy 60 61 control values. Deuterium labelling revealed that the production rates of most lymphocyte subsets, 62 even those that had already reconstituted, were significantly higher in patients post-autoHSCT than in 63 healthy individuals. These increased rates of T- and B-cell production could only be reconciled with the

64 observed slow changes in lymphocyte numbers over time if lymphocyte loss rates were also 65 significantly increased, impeding a timely reconstitution of the lymphocyte pool post-autoHSCT.

# 66 Materials and Methods

67 Complete Materials and Methods can be found as Supplementary Information.

#### 68 Patient characteristics

69 Six patients who received an autoHSCT for the treatment of a hematologic malignancy were 70 enrolled in the study after having provided written informed consent. Following repeated 71 subcutaneous injections with granulocyte-colony stimulating factor (G-CSF), stem cells were obtained 72 by leukapheresis of peripheral blood. Patients received a non T-cell depleted graft; the average number of CD34<sup>+</sup> cells transplanted was 5.03x10<sup>6</sup> cells/kg (median, 4.12; range, 1.82-12.38). Patients were 73 74 included in the study between 196 and 420 days after autoHSCT, and had no signs of transplantation-75 related complications, severe infections (HIV, HBV, HCV), other liver disease, active uncontrolled 76 infections (such as infectious mononucleosis), inadequate liver or kidney function, or cardiovascular 77 disease before and during the study. Additional inclusion criteria were: fully transfusion-independent at start of the study, hemoglobin level  $\geq$ 6mmol/l, and platelet count  $\geq$ 50x10<sup>9</sup>/L. Any use of medication 78 79 during the study was unrelated to the malignancy and the HSCT (Figure 1). In order to compare the 80 phenotypes of the B- and T-cell compartments of patients to those of age-matched healthy individuals, we used data from healthy individuals from a previous study <sup>16</sup>, and additional blood samples were 81 collected from healthy volunteers not following the labelling protocol after having provided informed 82 83 consent. This study was approved by the medical ethical committee of the University Medical Center 84 Utrecht and conducted in accordance with the Helsinki Declaration.

# 85 In vivo deuterium labelling

*In vivo* deuterium labelling was performed as previously described with small adaptations <sup>16</sup>. Briefly, patients received an oral ramp-up dose of 7.5 ml of heavy water (<sup>2</sup>H<sub>2</sub>O, 99.8% enriched, Cambridge Isotope Laboratories) per kg body water on the first day of the study, and drank a daily maintenance dose of 1.25 ml <sup>2</sup>H<sub>2</sub>O per kg body water for 6 weeks. To reduce the study burden, the labelling period of patients was 3 weeks shorter than the previously used labelling period for healthy individuals.

# 92 Cell isolation, flow cytometry and cell sorting

Peripheral blood mononuclear cells were obtained by Ficoll-Paque (GE Healthcare, Little
Chalfont, UK) density gradient centrifugation from heparinized blood. Granulocytes were obtained by
2 cycles of erythrocyte lysis (155mM NH4Cl, 10mM KHCO3, 0.1mM Na2-EDTA, pH=7.0) of the

96 granulocyte/erythrocyte layer. To determine baseline enrichment, total peripheral blood mononuclear 97 cells were frozen on the first day of the study, prior to  ${}^{2}\text{H}_{2}\text{O}$  intake.

Absolute cell numbers were determined using TruCount tubes (BD Biosciences, San Jose, CA,
 USA), and cell cycle analysis was performed by measuring expression of Ki-67. Samples were analysed
 on an LSR-II or LSR-Fortessa flow cytometer using FACS Diva software (BD Biosciences).
 CD19<sup>+</sup> naive (IgM<sup>+</sup>CD27<sup>-</sup>), Ig class-switched (IgM<sup>-</sup>CD27<sup>+</sup>) and IgM<sup>+</sup> (IgM<sup>+</sup>CD27<sup>+</sup>) memory B-cells
 and CD3<sup>+</sup>CD4<sup>+</sup> and CD3<sup>+</sup>CD8<sup>+</sup> naive (CD27<sup>+</sup>CD45RO<sup>-</sup>) and memory (CD45RO<sup>+</sup>) T-cells were sorted on a
 FACSAria II or FACSAria III cell sorter using FACS Diva software (BD Biosciences). Flow cytometric
 analyses and cell sorting were always performed on freshly isolated material. Representative density

dot plots and the gating strategy for TruCount analysis and cell sorting are shown in Sup. Figure 1.

### 106 Statistical analyses

107 Medians were compared between groups using Mann–Whitney tests. Correlations were 108 analysed using the Spearman's rank test (GraphPad Software, Inc). Differences with a p-value<0.05 109 were considered significant.

# 110 Results

### 111 Heterogeneous T-cell reconstitution kinetics post-autoHSCT

112 To investigate whether lymphocyte production and loss depend on cell numbers during lymphopenia in humans, we quantified the production and loss rates of B- and T-cells in 6 patients who 113 114 received an autoHSCT for the treatment of haematological malignancies. Patients were included in the study between 196 days and 420 days post-autoHSCT, they received deuterated water ( ${}^{2}H_{2}O$ ) for six 115 116 weeks, and were followed for approximately one year after start of the labelling period (Figure 1). 117 Patient B withdrew from the study 10 weeks after the start of  ${}^{2}H_{2}O$  labelling due to infectious 118 complications unrelated to participation in the study. All other patients had no complications that 119 needed treatment during the study follow-up, which was supported by CRP levels in the normal range 120 (Sup. Figure 2).

The sub-optimal T-cell recovery observed in the peripheral blood of patients post auto-HSCT (Figure 2A) was largely due to the slow reconstitution of CD4<sup>+</sup> T-cells (Figure 2B). At the start of  ${}^{2}H_{2}O$ labelling, CD8<sup>+</sup> T-cell numbers had reached normal levels in most patients, whereas CD4<sup>+</sup> T-cell numbers remained below normal levels even 1.5 years post-autoHSCT. This resulted in an inverse CD4:CD8 ratio in all patients except for *patient C* (Figure 2C), who experienced extremely slow CD8<sup>+</sup> Tcell reconstitution (Figure 2D). Naive (CD45RO<sup>-</sup>CD27<sup>+</sup>) CD4<sup>+</sup> T-cell numbers remained below normal levels throughout the 2-year follow-up period, whereas memory (CD45RO<sup>+</sup>) CD4<sup>+</sup> T-cells reached the 128 lower range of normal levels around 400 days post-autoHSCT (Figure 2B). Naive and memory CD8<sup>+</sup> T-129 cell numbers were at normal or supra-normal levels at the start of the study in all patients except for 130 patient C (Figure 2D). In line with cell numbers, for most patients the fractions of naive cells, central memory (CM, CD45RO<sup>+</sup>CD27<sup>+</sup>), effector memory (EM, CD45RO<sup>+</sup>CD27<sup>-</sup>) and effector (CD45RO<sup>-</sup>CD27<sup>-</sup>) T-131 cells differed from those in healthy controls and varied slightly over time (Figure 2E and Sup. Figure 3). 132 Because it is generally assumed that during lymphopenia the availability of growth and survival 133 factors increases, which has in particular been shown for IL-7 plasma levels <sup>18–22</sup>, we also determined 134 135 plasma levels of IL-7 and IL-15 between 12 and 24 months post-autoHSCT. Despite the CD4<sup>+</sup> T-cell 136 lymphopenia observed in these patients, their plasma concentrations of IL-7 and IL-15 and several 137 other cytokines were in the range of those of healthy controls (Sup. Figure 2).

## 138 Increased CD4<sup>+</sup> and CD8<sup>+</sup> T-cell production rates post-autoHSCT

139 To investigate whether low CD4<sup>+</sup> T-cell numbers were associated with increased T-cell 140 production rates, we compared the level of deuterium enrichment in the DNA of the different T-cell 141 subsets between patients and controls. Deuterium enrichment analysis showed a relatively high level 142 of label incorporation in patients, despite the fact that the labelling period was 3 weeks shorter for 143 patients than for controls (Figure 3A). Using mathematical modelling we estimated the production 144 rates of the different T-cell subsets (i.e. the number of new cells produced per day, coming from a 145 source or peripheral cell division, divided by the number of resident cells in the population). We found 146 that the production rates of naive and memory CD4<sup>+</sup> T-cells were, respectively, 6-times and 3-times 147 higher in patients than in controls. For naive and memory CD8<sup>+</sup> T-cells, the estimated production rates 148 were approximately 8- and 4-times higher in patients compared to controls (Figure 3B, Sup. Table 1), 149 despite the fact that absolute CD8<sup>+</sup> T-cell numbers had already recovered to healthy levels 12 months 150 post-transplantation.

#### 151 Increased proliferation of naive but not memory CD4<sup>+</sup> and CD8<sup>+</sup> T cells

152 T-cell production rates as measured by deuterium labelling may reflect cell division of the subset 153 of interest or an influx of cells from a source (e.g. by thymic output) or from another subset (e.g. 154 through lymphocyte differentiation). To distinguish between these options, we first measured Ki-67 expression, a marker for peripheral cell division, of all lymphocyte subsets. The fraction of Ki-67<sup>+</sup> cells 155 within the naive CD4<sup>+</sup> and CD8<sup>+</sup> T-cell pools was significantly higher in patients compared to controls 156 157 (Figure 4A). For the memory T-cell subsets, in contrast, the fraction of Ki-67<sup>+</sup> cells of patients did not 158 differ significantly from those of controls (Figure 4A). This suggests that the increased production rates 159 of memory CD4<sup>+</sup> and CD8<sup>+</sup> T-cells may occur due to an increased influx from naive T-cells into the 160 memory compartment, rather than increased T-cell division within the memory T-cell pools.

161 Besides increased cell division in the naive T-cell pool, increased naive T-cell production rates post-autoHSCT could in theory also be due to increased thymic output. T-cell receptor excision 162 163 circles (TRECs) are commonly measured to estimate thymopolesis. Because the average TREC content per T-cell declines with age <sup>23–25</sup>, we measured TREC contents of naive T-cells from patients, 164 cord blood, and young (on average 23 years of age) and aged (on average 68 years of age) healthy 165 166 individuals <sup>16</sup>. The average TREC content of naive CD4<sup>+</sup> T-cells in patients was approximately 10-fold 167 higher than in aged controls, and not significantly different from that of young individuals and cord 168 blood (Figure 4B), even though all but one of the patients were more than 50 years of age. For naive 169 CD8<sup>+</sup> T-cells, the average TREC content in patients was in the range of young and aged controls (Figure 170 4B). We also measured CD31 expression on naive CD4<sup>+</sup> T-cells, as CD31<sup>+</sup>CD4<sup>+</sup> T cells are known to be enriched in recent thymic emigrants (RTEs) <sup>26,27</sup>. The fraction of CD31<sup>+</sup> cells within the naive CD4<sup>+</sup> T-171 172 cell population was slightly higher in patients than in aged controls and slightly lower than in young controls and cord blood (Figure 4C, Sup. Figure 4). For naive T-cells, the combined Ki-67, TREC and 173 174 CD31 data suggest that the increased T-cell production is due to increased T-cell division, and that the 175 increased average TREC contents and percentages of CD31<sup>+</sup> cells may be a direct consequence of normal thymic output entering a smaller T-cell pool <sup>28</sup>. 176

### 177 Heterogeneous B-cell reconstitution kinetics post-autoHSCT

178 Next, we studied the changes in B-cell dynamics following autoHSCT. Although total CD19<sup>+</sup> B-179 cell numbers and naive (IgM<sup>+</sup>CD27<sup>-</sup>) B-cell numbers had already reached normal or even supra-normal 180 levels by day 200 post-autoHSCT, Ig class-switched (IgM<sup>-</sup>CD27<sup>+</sup>) and IgM<sup>+</sup> (IgM<sup>+</sup>CD27<sup>+</sup>) memory B-cell 181 numbers in most patients were still below, or in the lower range of, those of healthy controls 182 throughout the study period (Figure 5A, 5B and Sup. Figure 5).

### 183 Increased production rates of B-cells post-autoHSCT

We analysed the deuterium enrichment of the different B-cell subsets to study whether B-cell production rates were increased for subsets which were still low in cell numbers (Figure 6A). The production rates of Ig switched-memory B-cells and IgM<sup>+</sup> memory B-cells were 3.5-times and 5-times higher than in controls, respectively (Figure 6B, Sup. Table 1). Also the production rate of naive B-cells, a population that had already reconstituted to supra-normal levels, remained significantly higher than in healthy controls (Figure 6B, Sup. Table 1).

Because B-cell production may depend on peripheral B-cell division and on *de novo* bone marrow output, we measured Ki-67 expression and kappa-deleting recombination excision circles (KRECs), in an attempt to estimate bone marrow output. The percentages of dividing, i.e. Ki-67<sup>+</sup>, cells within IgM<sup>+</sup> and Ig switched-memory B-cells were significantly higher in patients than in healthy

individuals (Figure 6C). In contrast, the fraction of Ki-67<sup>+</sup> cells within the naive B-cell subset was similar
between patients and controls (Figure 6C). Although naive B-cell peripheral division rates were not
increased post-autoHSCT, their production rates were 2-times higher than in controls. The replication
history (measured as number of cell divisions) of the naive B-cell subsets in patients tended to be lower
than in controls (although not significantly), suggesting that the output of naive B-cells from the bone
marrow rather than their peripheral proliferation rate was increased after autoHSCT (Figure 6D).

#### 200 Increased lymphocyte production rates are counteracted by increased lymphocyte loss rates

The increased lymphocyte production rates that we observed in patients after autoHSCT may at first sight suggest that, also in humans, lymphocyte production is regulated in a density-dependent manner. The observation that lymphocyte production rates were also elevated for subsets for which cell numbers had already normalized, however, challenges this interpretation. Another observation challenging this interpretation is that for most subsets, lymphocyte numbers increased very little over time, despite the significant increase in lymphocyte production. This suggests that lymphocyte loss rates were also significantly increased after autoHSCT.

208 To estimate the average loss rates of all lymphocyte subsets (i.e. the number of cells lost per 209 day, by cell death, migration or differentiation, divided by the number of resident cells in the 210 population), we used the average lymphocyte production rates estimated from the deuterium labelling 211 experiments and an exponential function to describe the changes in cell numbers of each lymphocyte 212 subset over time (see Sup. material and methods). For most T-cell and B-cell subsets the average loss 213 rate was approximately 3 to 5-times higher post-autoHSCT than in healthy individuals (Figure 7, Sup. 214 Table 2). For naive CD8<sup>+</sup> T-cells the average loss rate was even 9.5-times higher in patients than in 215 healthy individuals (Figure 7, Sup. Table 2). Thus, despite the fact that production rates are clearly 216 increased in patients post-autoHSCT, this increased production goes hand in hand with increased 217 lymphocyte loss rates, thereby challenging the view that it reflects a homeostatic response to low 218 lymphocyte numbers.

# 219 Discussion

From a homeostatic viewpoint, a response to low lymphocyte numbers could take the form of increased lymphocyte production or decreased lymphocyte loss. Based on the observation that severe lymphopenia in mice is associated with increased peripheral proliferation <sup>3–5,20</sup>, it is widely believed that lymphocyte production rates are increased when cell numbers are low. We have previously shown that naive T-cell turnover rates do not increase to compensate for the at least 10-fold decline in thymic output in elderly individuals <sup>16</sup>. This could be due to the relatively small degree of naive T-cell loss observed during healthy ageing. Under more severe conditions of lymphopenia in humans, high
 frequencies of proliferating lymphocytes have been observed, but these have been linked to immune
 activation and clinical events, e.g. GVHD and opportunistic infections <sup>14</sup>. Thus, there is no convincing
 evidence that homeostatic regulation of lymphocyte production and loss occurs in humans.

230 Our deuterium labelling study shows that in patients receiving an autoHSCT, in the absence of 231 GVHD, clinically manifested infections and transplantation-related complications, the production rates 232 of most T- and B-cell subsets were significantly increased 12 months after transplantation. Increased 233 lymphocyte production following lymphodepletion has generally been interpreted as evidence for a density-dependent response to low lymphocyte numbers <sup>12,13,15,29,30</sup>. Our study challenges this view for 234 235 two reasons: i) T- and B-cell production rates did not normalize when cell numbers did, and ii) lymphocyte loss rates were also increased post-autoHSCT. This suggests that the increase in 236 237 lymphocyte production rates in autoHSCT patients was not simply a homeostatic response to low cell-238 numbers. Other determinants, such as repertoire diversity or the clonality of the T-cell pool might also 239 play a role. In addition, despite the fact that the patients in our study were included up to 12 months 240 post-transplantation and were selected on the basis of being in good health, we cannot exclude that 241 the increased rates of lymphocyte production and loss in these patients reflect HSCT-related 242 complications, such as the impact of initial chemo-therapy and conditioning-therapy or sub-clinical 243 infections and inflammation, which may have gone unnoticed.

244 The observation that lymphocyte loss rates were increased post-autoHSCT is remarkable in the 245 light of the widely held view that homeostatic mechanisms could take the form of increased 246 lymphocyte survival. This concept is supported by the observation that the availability of pro-survival and anti-apoptotic factors, such as IL-7<sup>31</sup>, increases during lymphopenia. We found that lymphocyte 247 248 loss rates were up to 10-fold increased after autoHSCT. This is in line with previous human studies on 249 T-cell survival after allogenic HSCT, which consistently reported that the fraction of pro-apoptotic cells increases following transplantation <sup>15,32–34</sup>. Although this suggests that intervention with lymphocyte 250 251 survival after HSCT may aid lymphocyte reconstitution, in our study, different factors may have 252 contributed to the loss of cells from the peripheral blood. Cells may have been lost from the circulation 253 by cell death, but also by lymphocyte differentiation and/or migration to the tissues. Further studies 254 need to clarify whether lymphocyte reconstitution occurs at similar rates in blood and tissues, or 255 whether lymphocyte recruitment to the tissues may be a key factor influencing the loss of lymphocytes 256 from the blood following autoHSCT.

257 Consistent with previous reports <sup>10,15,35</sup>, we found that 12 months post-autoHSCT, CD4<sup>+</sup> T-cell 258 numbers were below the normal range while CD8<sup>+</sup> T-cells recovered more rapidly. Deuterium labelling 259 in patients revealed that the average production rates of most T-cell subsets were significantly 260 increased following autoHSCT. This increase was especially evident for naive T-cells. The high 261 percentage of Ki-67<sup>+</sup> naive T-cells post-autoHSCT suggests that increased naive T-cell production is to a large extent explained by increased peripheral T-cell proliferation. Memory T-cell production rates 262 263 (based on deuterium enrichment) were also higher in patients compared to controls, while Ki-67 expression suggested that memory CD4<sup>+</sup> and CD8<sup>+</sup> T-cell proliferation rates were not increased after 264 265 autoHSCT. This seeming contradiction may be explained by the fact that Ki-67, a snapshot marker, may 266 be less sensitive to detect differences in T-cell proliferation than long-term *in vivo* deuterium labelling. 267 Alternatively, the increased production rate of memory T cells post-autoHSCT may be due to increased 268 transition of naive T cells into the memory T-cell population. In mice it has been demonstrated that 269 naive T-cells adoptively transferred into immunodeficient animals can undergo division without 270 cognate antigen stimulation, thereby acquiring a memory phenotype <sup>36,37</sup>.

271 If a significant part of cell production in a certain lymphocyte subset (e.g. the memory subset) is 272 indeed due to an influx from another lymphocyte subset (e.g. the naive subset), the increased 273 production rates that we observed may either reflect a true increase in cell production, or a normal 274 influx of cells entering a smaller lymphocyte population. To distinguish between these options, for 275 each lymphocyte subset and each individual, we also calculated the total number of cells produced per 276 day (i.e. coming from a source and/or from peripheral cell division), by multiplying the average 277 production rate of each lymphocyte subset with the median cell number of that subset, and compared 278 these values to those in healthy controls (data not shown). We found that total daily lymphocyte 279 production was as high as in healthy controls for naive CD4<sup>+</sup>T cells and higher than in healthy controls 280 for all other lymphocyte subsets, suggesting that the increased lymphocyte production rates post-281 autoHSCT truly reflected increased T-cell proliferation and/or an increased influx from another lymphocyte compartment. 282

283 Measuring thymopoiesis and the contribution of recent thymic emigrants to the naive T-cell 284 pool after HSCT is not straightforward. Although increased TREC contents at first sight seem 285 suggestive for increased thymic output, T-cells bearing TRECs may in fact be overrepresented in the 286 peripheral T-cell pool post-transplantation when cell numbers are low <sup>28</sup>. Hence, for naive CD4<sup>+</sup> T cells, 287 whose numbers had not yet normalized, increased average TREC contents may incorrectly be 288 interpreted as evidence for increased thymic output. The finding that the average TREC content of 289 naive CD4<sup>+</sup>T-cells following autoHSCT was higher than in age-matched controls provides no evidence 290 that thymic output following transplantation was higher than in healthy controls, but does imply that 291 the thymus had become functional again within 12 months after intense conditioning for autoHSCT. 292 The fact that the average TREC content of naive CD4<sup>+</sup> T -cells, but not that of naive CD8<sup>+</sup> T-cells, was 293 higher in patients than in healthy individuals may reflect differences in the degree of depletion of naive 294 CD4<sup>+</sup> and CD8<sup>+</sup> T -cells. Alternatively, it might reflect differences in the way CD4<sup>+</sup> and CD8<sup>+</sup> T-cells are 295 generated. In support of the latter explanation, repertoire analyses in patients receiving an autoHSCT

for the treatment of autoimmune diseases have suggested that CD4<sup>+</sup> T-cells largely arise *de novo*, since
 most CD4<sup>+</sup> T-cell clones post-autoHSCT were not present at baseline, while CD8<sup>+</sup> T-cells mainly expand
 from cells that were already circulating pre-transplantation <sup>38–40</sup>.

299 To study in a population other than T-cells whether lymphocyte production and loss rates in 300 humans are regulated in a density-dependent manner, we quantified the production and loss rates of different B-cell subsets. In line with previous reports <sup>41-43</sup>, we found that 12 months after 301 302 transplantation, naive B-cell numbers had reconstituted to healthy (or even higher than healthy) 303 control values, while Ig class-switched and IgM<sup>+</sup> memory B-cells had not yet fully recovered. The 304 delayed reconstitution of Ig class-switched and IgM<sup>+</sup> memory B-cells has typically been attributed to 305 treatment-related damage to secondary lymphoid organs, which may hamper the formation of 306 germinal centers essential for somatic hypermutation and isotype switching <sup>42</sup>. Also for naive, Ig class-307 switched, and IgM<sup>+</sup> memory B-cells, we found that not only production rates but also cell loss rates 308 were increased 12 months post-autoHSCT, further supporting our conclusion that increased 309 lymphocyte production rates do not simply reflect a homeostatic response to low lymphocyte 310 numbers.

In brief, our findings show that despite the slow reconstitution of lymphocytes in autoHSCT patients, lymphocyte production rates are increased is. Since this increased production goes hand in hand with increased cell loss, and does not normalize when cell numbers do, it is not simply due to homeostatic mechanisms. Future studies should address whether the dynamics of lymphocytes after autoHSCT normalize in the long run, what drives the increase in lymphocyte production and loss rates during immune reconstitution, and to what extent immune reconstitution in the tissues occurs.

# 317 Acknowledgments

We thank the patients for their participation in this study, Jeroen F. van Velzen, Pien A.J. van der Burght and Gerrit Spierenburg for assistance with cell sorting, Laura Ackermans for theoretical input, Lyanne Derksen for critically reading the manuscript, Mr Benjamin Bartol and Ms Pei Mun Aui for technical support, and the nurses from the Julius Center Trial Unit for taking care of study participants.

### 322 Funding

The research leading to these results has received funding from the European Union Seventh Framework Programme (FP7/2007–2013) through the Marie-Curie Action "Quantitative T cell Immunology" Initial Training Network, with reference number FP7-PEOPLE-2012-ITN 317040-QuanTI and from the Landsteiner Foundation for Blood Transfusion Research (LSBR grant 0812).

# 327 Authorship

328 Contribution: MB-P, VvH, JD, JB and KT designed the experiments; MB-P and VvH performed the 329 experiments; LvdW and AJ selected and included the patients; MB-P, VH, JD, RdB, JB and KT analysed 330 and interpreted data; JD, RdB, and JB performed mathematical modelling; and all authors wrote and 331 approved the manuscript.

# 332 Conflict-of-interest statements

333 The authors declare no competing financial interests.

334

# 335 References

- Lin Y, Kim J, Metter EJ, et al. Changes in blood lymphocyte numbers with age in vivo and their association
   with the levels of cytokines/cytokine receptors. *Immun. Ageing.* 2016;13(1):24.
- Wertheimer AM, Bennett MS, Park B, et al. Aging and Cytomegalovirus Infection Differentially and Jointly
   Affect Distinct Circulating T Cell Subsets in Humans. J. Immunol. 2014;192(5):2143–2155.
- Freitas AA, Rocha B. Population Biology of Lymphocytes: The Flight for Survival. *Annu. Rev. Immunol.* 2000;18(1):83–111.
- Miller R a, Stutman O. T cell repopulation from functionally restricted splenic progenitors: 10,000-fold
   expansion documented by using limiting dilution analyses. *J. Immunol.* 1984;133(6):2925–32.
- 3445.Bell EB, Sparshott SM, Drayson MT, Ford WL. The stable and permanent expansion of functional T345lymphocytes in athymic nude rats after a single injection of mature T cells. J. Immunol. 1987;139(5):1379–34684.
- Neujahr DC, Chen C, Huang X, et al. Accelerated Memory Cell Homeostasis during T Cell Depletion and
   Approaches to Overcome It. *J. Immunol.* 2006;176(8):4632–4639.
- Gaudin E, Rosado M, Agenes F, McLean A, Freitas AA. B-cell homeostasis, competition, resources, and
   positive selection by self-antigens. *Immunol. Rev.* 2004;197:102–15.

Heining C, Spyridonidis A, Bernhardt E, et al. Lymphocyte reconstitution following allogeneic
 hematopoietic stem cell transplantation: a retrospective study including 148 patients. *Bone Marrow Transplant.* 2007;39(10):613–622.

- Ringhoffer S, Rojewski M, Dohner H, Bunjes D, Ringhoffer M. T-cell reconstitution after allogeneic stem
   cell transplantation: assessment by measurement of the sjTREC/ TREC ratio and thymic naive T cells.
   *Haematologica*. 2013;98(10):1600–1608.
- Bosch M, Khan FM, Storek J. Immune reconstitution after hematopoietic cell transplantation. *Curr. Opin. Hematol.* 2012;19(4):324–335.
- 11. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin.

360		Immunol. 2007;19(5):318–330.
361	12.	Jones JL, Thompson SAJ, Loh P, et al. Human autoimmunity after lymphocyte depletion is caused by
362		homeostatic T-cell proliferation. Proc. Natl. Acad. Sci. 2013;110(50):20200–20205.
363	13.	Bouvy AP, Kho MML, Klepper M, et al. Kinetics of homeostatic proliferation and thymopoiesis after ratg
364		induction therapy in kidney transplant patients. <i>Transplantation</i> . 2013;96(10):904–913.
365	14.	Hazenberg MD. T-cell receptor excision circle and T-cell dynamics after allogeneic stem cell
366		transplantation are related to clinical events. <i>Blood</i> . 2002;99(9):3449–3453.
367	15.	Alho AC, Kim HT, Chammas MJ, et al. Unbalanced recovery of regulatory and effector T cells after
368		allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> . 2017;127(5):646–658.
369	16.	Westera L, van Hoeven V, Drylewicz J, et al. Lymphocyte maintenance during healthy aging requires no
370		substantial alterations in cellular turnover. Aging Cell. 2015;14(2):219–227.
371	17.	R Core Team (R Foundation for Statistical Computing). R: A Language and Environment for Statistical
372		Computing. 2018;
373	18.	Van Gent R, Schadenberg AWL, Otto SA, et al. Long-term restoration of the human T-cell compartment
374		after thymectomy during infancy: A role for thymic regeneration? <i>Blood</i> . 2011;118(3):627–634.
375	19.	Sauce D, Larsen M, Fastenackels S, et al. Lymphopenia-Driven Homeostatic Regulation of Naive T Cells in
376		Elderly and Thymectomized Young Adults. J. Immunol. 2012;189(12):5541–5548.
377	20.	Fry TJ, Connick E, Falloon J, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood.
378		2001;97(10):2983–90.
379	21.	Napolitano LA, Grant RM, Deeks SG, et al. Increased production of IL-7 accompanies HIV-1-mediated T-
380		cell depletion: implications for T-cell homeostasis. Nat. Med. 2001;7(1):73–79.
381	22.	Bolotin E, Annett G, Parkman R, Weinberg K. Serum levels of IL-7 in bone marrow transplant recipients:
382		relationship to clinical characteristics and lymphocyte count. Bone Marrow Transplant. 1999;23(8):783-
383		788.
384	23.	Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment
385		of HIV infection. Nature. 1998;396(6712):690–695.
386	24.	Hazenberg MD, Otto SA, Cohen Stuart JW, et al. Increased cell division but not thymic dysfunction rapidly
387		affects the T-cell receptor excision circle content of the naive T cell population in HIV-1 infection. Nat.
388		Med. 2000;6(9):1036–42.
389	25.	Hazenberg MD, Verschuren MC, Hamann D, Miedema F, Dongen JJ. T cell receptor excision circles as
390		markers for recent thymic emigrants: Basic aspects, technical approach, and guidelines for
391		interpretation. J. Mol. Med. 2001;79(11):631–640.
392	26.	Kohler S, Thiel A. Life after the thymus: CD31+ and CD31- human naive CD4+ T-cell subsets. Blood.
393		2009;113(4):769–774.
394	27.	van den Broek T, Borghans JAM, van Wijk F. The full spectrum of human naive T cells. Nat. Rev. Immunol.
395		2018;18(June):
396	28.	Hazenberg MD, Borghans JAM, de Boer RJ, Miedema F. Thymic output: a bad TREC record. Nat. Immunol.
397		2003;4(2):97–99.

- 398 29. Havenith SHC, Remmerswaal EBM, Bemelman FJ, et al. Rapid T cell repopulation after rabbit antithymocyte globulin (rATG) treatment is driven mainly by cytomegalovirus. *Clin. Exp. Immunol.*2012;169(3):292–301.
- 401 30. Bouvy AP, Klepper M, Betjes MGH, et al. Alemtuzumab as Antirejection Therapy. *Transplant. Direct*.
  402 2016;2(6):e83.
- 403 31. Ponchel F, Cuthbert RJ, Goëb V. IL-7 and lymphopenia. *Clin. Chim. Acta*. 2011;412(1–2):7–16.
- Brugnoni D, Airò P, Pennacchio M, et al. Immune reconstitution after bone marrow transplantation for
  combined immunodeficiencies: down-modulation of Bcl-2 and high expression of CD95/Fas account for
  increased susceptibility to spontaneous and activation-induced lymphocyte cell death. *Bone Marrow Transplant.* 1999;23(5):451–457.
- 408 33. Lin MT, Tseng LH, Frangoul H, et al. Increased apoptosis of peripheral blood T cells following allogeneic
  409 hematopoietic cell transplantation. *Blood*. 2000;95(12):3832–9.
- 410 34. Poulin J-F. Evidence for adequate thymic function but impaired naive T-cell survival following allogeneic
  411 hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease. *Blood*.
  412 2003;102(13):4600–4607.
- 413 35. Storek J, Geddes M, Khan F, et al. Reconstitution of the immune system after hematopoietic stem cell
  414 transplantation in humans. *Semin. Immunopathol.* 2008;30(4):425–37.
- 415 36. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasis-stimulated proliferation drives naive T cells to
  416 differentiate directly into memory T cells. J. Exp. Med. 2000;192(4):549–56.
- 417 37. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during
  418 homeostasis-driven proliferation. J. Exp. Med. 2000;192(4):557–64.
- 419 38. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after
  420 autologous stem cell transplantation in multiple sclerosis patients. *J. Exp. Med.* 2005;201(5):805–816.
- 421 39. Muraro PA, Robins H, Malhotra S, et al. T cell repertoire following autologous stem cell transplantation
  422 for multiple sclerosis. *J. Clin. Invest.* 2014;124(3):1168–72.
- 42. Dubinsky AN, Burt RK, Martin R, Muraro PA. T-cell clones persisting in the circulation after autologous
  hematopoietic SCT are undetectable in the peripheral CD34+ selected graft. *Bone Marrow Transplant*.
  425 2010;45(2):325–331.
- 41. Burns LJ, Weisdorf DJ, DeFor TE, et al. IL-2-based immunotherapy after authologous transplantation for
  lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial. *Bone*Marrow Transplant. 2003;32(2):177–186.
- 42. Avanzini MA, Locatelli F, Santos C Dos, et al. B lymphocyte reconstitution after hematopoietic stem cell
  430 transplantation: functional immaturity and slow recovery of memory CD27+ B cells. *Exp. Hematol.*431 2005;33(4):480–486.
- 43. Bemark M, Holmqvist J, Abrahamsson J, Mellgren K. Translational Mini-Review Series on B cell subsets in
  433 disease. Reconstitution after haematopoietic stem cell transplantation revelation of B cell
  434 developmental pathways and lineage phenotypes. *Clin. Exp. Immunol.* 2012;167(1):15–25.

# 435 Figure legends

Time (month	ns) -12			-6	0	6		12
		1	time after au	toHSCT	²H <sub>2</sub> O labelling	study follow-up		
			Patie	nt A				
		Pat	tient B 💼					
	F	Patient C 💼				1 1	<u> </u>	
	Patient D						L	
Patient E								
Patient F								
Patient	Symbol	Age	Sex	Malignancy	Induction therapy	Conditioning Regimen	Time post- HSCT	Medication usage
	<u> </u>			Acute myeloid				
A	0	27	М	leukemia	A A HOVON 132 arm	Busulfan, Cyclosporine	196 days	Valaciclovir
B	•	27 53	M F	leukemia Multiple myeloma	A VCD, VMP-arm, VRD	Busulfan, Cyclosporine Melphalan	196 days 245 days	Valaciclovir Pamidronate
B	•	27 53	M F	leukemia Multiple myeloma Non Hodgkin	A VCD, VMP-arm, VRD	Busulfan, Cyclosporine Melphalan	196 days 245 days	Valaciclovir Pamidronate
A B C	•	27 53 61	M F M	leukemia Multiple myeloma Non Hodgkin lymphoma (mantle cell lymphoma)	A VCD, VMP-arm, VRD R-CHOP, Ara-C	Busulfan, Cyclosporine Melphalan BEAM	196 days 245 days 287 days	Valaciclovir Pamidronate Triamterene
A B C D	•	27 53 61 57	M F M	leukemia Multiple myeloma Non Hodgkin lymphoma (mantle cell lymphoma) Multiple myeloma	A VCD, VMP-arm, VRD R-CHOP, Ara-C TAD	Busulfan, Cyclosporine Melphalan BEAM Melphalan	196 days 245 days 287 days 355 days	Valaciclovir Pamidronate Triamterene Omeprazole
A B C D E	•	27 53 61 57 51	M F M M	leukemia Multiple myeloma Non Hodgkin lymphoma (mantle cell lymphoma) Multiple myeloma	A VCD, VMP-arm, VRD R-CHOP, Ara-C TAD VRD	Busulfan, Cyclosporine Melphalan BEAM Melphalan Melphalan	196 days 245 days 287 days 355 days 414 days	Valaciclovir Pamidronate Triamterene Omeprazole

### 436

437 Figure 1. Study protocol timeline and patient characteristics. (A) Summary figure depicting the study time line of every patient. Patients are centred by start of <sup>2</sup>H<sub>2</sub>O labelling. The left bar indicated the 438 439 time between the autologous hematopoietic stem cell transplantation (autoHSCT) and the start of the labelling period, the grey area indicates the 6 weeks <sup>2</sup>H<sub>2</sub>O labelling period, the right bar provides the 440 441 follow up period and the vertical bars indicate the blood sampling time points. (B) Patient characteristics. Age=Age at start <sup>2</sup>H<sub>2</sub>O labelling; M=Male; F=Female; Time post-HSCT=Reconstitution 442 443 period at start <sup>2</sup>H<sub>2</sub>O labelling; Medication usage=Medication during the study; HOVON 132 arm A 444 (Idarubicin, Ara-C (Cytarabine), Daunorubicin); VCD (Bortezomib, Cyclophosphamide, Dexamethason); 445 VMP (Bortezomib, Melphalan, Prednisone); VRD (Bortezomib, lenalidomide, dexamethasone); R-CHOP (Rituximab, Cyclophosphamide, Adriamycin, Vincristin, Prednisone); Ara-C (Cytarabine), TAD 446 447 (Thalidomide, Adriamycin, Dexamethasone); CTD (Carfilzomib, Thalidomide, Dexamethasone); BEAM 448 (Carmustine, Etoposide, Ara-C (Cytarabine), Melphalan). For absolute leukocytes, neutrophils, lymphocytes and monocytes numbers see Sup. Figure 6. 449



Figure 2. T-cell reconstitution following autoHSCT. (A) Absolute numbers (cells per milliliter) of total 451 452 CD3<sup>+</sup>T-cells. (B) Absolute numbers (cells per milliliter) of CD4<sup>+</sup>T-cells (CD3<sup>+</sup>CD4<sup>+</sup>), naive (CD27<sup>+</sup>CD45RO<sup>-</sup> ) and memory (CD45RO<sup>+</sup>) CD4<sup>+</sup> T-cells. (C) CD4:CD8 ratio. (D) Absolute numbers (cells per milliliter) of 453 CD8<sup>+</sup> T-cells (CD3<sup>+</sup>CD8<sup>+</sup>), naive (CD27<sup>+</sup>CD45RO<sup>-</sup>) and memory (CD45RO<sup>+</sup>) CD8<sup>+</sup> T-cells. (A-D) Graphs 454 455 show the absolute cell counts per milliliter or the CD4:CD8 ratio in autoHSCT patients (patients A to F) over time from for the duration of the study, and the median and the corresponding IR for HCs (healthy 456 457 controls, grey area and whisker bars). (E) Bar graphs show the median percentage of naive (CD27<sup>+</sup>CD45RO<sup>-</sup>), central memory (CM, CD27<sup>-</sup>CD45RO<sup>+</sup>), effector memory (EM, CD27<sup>+</sup>CD45RO<sup>+</sup>) and 458 459 effector (CD27<sup>-</sup>CD45RO<sup>-</sup>) CD4<sup>+</sup> and CD8<sup>+</sup> T-cells of autoHSCT patients (patients A to F) and HCs (naive in blue, CM in orange, EM in green and effector in grey). For patient characteristics see Figure 1B, for 460 461 the T-cell subset distribution per patient over time see Sup. Figure 3.





462

Figure 3. T-cell dynamics after autoHSCT. (A) Deuterium enrichment in the DNA of naive and memory 463 464 CD4<sup>+</sup> and CD8<sup>+</sup> T-cells in autoHSCT patients (A to F, color symbols), and healthy controls (HCs, grey 465 symbols) <sup>16</sup>. Dotted lines correspond to the end of the labelling period (black for autoHSCT patients and grey for HCs). Label enrichment was scaled between 0 and 100% by normalizing for the maximum 466 enrichment in granulocytes (Sup. Figure 7). For individual fits see Sup. Figure 8. (B) Estimates of the 467 per cell production rate of naive and memory CD4<sup>+</sup> and CD8<sup>+</sup> T-cells in autoHSCT patients and HCs <sup>16</sup>. 468 Different symbols indicate different individuals, autoHSCT patients (A to F) in color and HCs in grey. 469 470 Horizontal lines represent median values. P-values of significant differences between groups are 471 shown.





Figure 4. Contribution of peripheral proliferation and thymic output to T-cell production after 473 474 autoHSCT. (A) Ki-67 expression was measured within naive and memory CD4<sup>+</sup> (left panel) and CD8<sup>+</sup> (right panel) T-cell in autoHSCT patients and HCs <sup>16</sup>. (B) Average number of TRECs per naive CD4<sup>+</sup> (left 475 panel) and CD8<sup>+</sup> (right panel) T-cell in autoHSCT patients, cord blood (CB) and healthy controls (HCs) 476 477 <sup>16</sup>. For *Patient A* and *Patient E*, TREC content was measured the first day of the study (t<sub>0</sub>) as well as the 478 last study visit (tend). For Patient D, TREC content was not successfully measured due to limited 479 material. (C) CD31 expression was measured within naive CD4<sup>+</sup> T-cells in autoHSCT patients, cord blood and HCs <sup>16</sup>. For changes in CD31 expression and absolute numbers of CD31<sup>+</sup> cells over time, see Sup. 480 Figure 4. Different symbols indicate different individuals, autoHSCT patients (A to F) in color, CB in dark 481 482 grey, and young (median age of 23 years) and old (median age of 68 years) HCs in light grey. Horizontal lines represent median values. P-values of significant differences between groups are shown. 483





Figure 5. B-cell reconstitution following autoHSCT. (A) Absolute numbers (cells per milliliter) of total 485 486 CD19<sup>+</sup> B-cells, naive (CD19<sup>+</sup>IgM<sup>+</sup>CD27<sup>-</sup>), Ig class-switched memory (CD19<sup>+</sup>IgM<sup>-</sup>CD27<sup>+</sup>) and IgM<sup>+</sup> memory 487 (CD19<sup>+</sup>IgM<sup>+</sup>CD27<sup>+</sup>) B-cells in peripheral blood over time. Graphs show the absolute cell counts per milliliter in autoHSCT patients (patients A to F) over the duration of the study, and the median and the 488 489 corresponding IR (interguartile rage) for HCs (healthy controls, grey area and whisker bars). (B) Bar graphs show the median percentage of naive, Ig class-switched memory and IgM<sup>+</sup> memory B-cells 490 491 within total CD19<sup>+</sup> B-cells of autoHSCT patients (patients A to F) and HCs (naive in blue, natural effector 492 in orange and memory in green). For the B-cell subset distribution per patient over time see Sup. Figure 493 5. Note the different y-axes in panel A.



Figure 6. B-cell dynamics after autoHSCT. (A) Deuterium enrichment in the DNA of naive, Ig classswitched memory and IgM<sup>+</sup> memory B-cells in autoHSCT patients (A to F, color symbols), and healthy
controls (HCs, grey symbols) <sup>16</sup>. Dotted lines correspond to the end of the labelling period (black for

autoHSCT patients and grey for HCs). Label enrichment was scaled between 0 and 100% by normalizing 498 499 for the maximum enrichment in granulocytes for each patient (Sup. Figure 8). For individual fits see Sup. Figure 9. (B) Estimates of the per cell production rates of naive, Ig class-switched memory and 500 IgM<sup>+</sup> memory B-cells in autoHSCT patients and HCs<sup>16</sup>. (C) Ki-67 expression was measured within naive, 501 502 Ig class-switched memory and IgM<sup>+</sup> memory B-cells in autoHSCT patients and HCs <sup>16</sup>. (D) Percentage of 503 naive B-cells containing a KREC and naive B-cell replication history for autoHSCT patients and HCs <sup>16</sup>. 504 Different symbols indicate different individuals, autoHSCT patients (A to F) in color and HCs in grey. 505 Horizontal lines represent median values. P-values of significant differences between groups are 506 shown.



Figure 7. Average T-cell and B-cell loss rates following autoHSCT. (A) Estimates of the average loss rates of naive and memory CD4<sup>+</sup> and CD8<sup>+</sup> T-cells and of (B) naive, Ig class-switched memory and IgM<sup>+</sup> memory B-cells in autoHSCT patients (A to F, color symbols), and healthy controls (HC, grey symbols) <sup>16</sup>. Average loss rates were calculated using the estimated average turnover rates and the corrected cell numbers (Sup. Figure 10 and 11) as described in supplementary material and methods. Horizontal lines represent median values. P-values of significant differences between groups are shown.

- 514
- 515
- 516
- 517
- 518
- 519